 SEATTLE, Jan. 29, 2021 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq:ATOS, a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has received 21 million from the exercise of outstanding warrants. The warrants were issued in financings in December 2020 and January 2021. 